The Neurotech Industry Investing and Partnering Conference 2009 will take place May 11-13, 2009 at the St. Regis Hotel, San Francisco. Here are some details:

May 11: Collaborating for Cures Summit
May 12-13: The Neurotech Industry Investing and Partnering Conference

Register now to Save $300. Please contact NIO by e-mail, fax or phone.

Neurotechnology Industry Organization
315 30th Street
San Francisco, CA 94131
(415) 341-0193 - main
(415) 358-5888 - fax
Email: zack(at)neurotechindustry.org

For reservations at St. Regis:
St. Regis
125 3rd St.
San Francisco CA
(415)284-4000

The St. Regis is a five star hotel conveniently located in SOMA district adjoining the San Francisco Museum of Modern Art.

Conference speakers include:

Novel Platforms in Neurodevice Development:
Frank Fischer, President and CEO, Neuropace
Ben Matteo, President and CEO, Eos Neuroscience
Andrew Thompson, CEO, Proteus Biomedical
Jamie Tyler, President and CEO, SynSonix
Session Chair: Kevin Wasserstein, Managing Director, Versant Ventures Next Generation Neuropsychiatry
Barry Brand, CEO, CeNeRx
Ian Massey, President and CEO, Synosia
Dan Segal, President North America, Brain Resource Company
Neal Simon, President and CEO, Azevan
Session Chair: Manuel Lopez-Figueroa, Vice President, Bay City Capital.

Investing in Neurotech Panel:
Ellen Baron, Partner, Oxford Bioscience Partners
Andrew Jay, Managing Partner, Siemens Venture Capital
Vincent Kim, Partner, Aberdare Ventures
Matthew Perry, Portfolio Manager, Biotechnology Value Fund
Moderator: Casey Lynch, NeuroInsights

Novel Platforms for CNS Drug Discovery and Neurodevice Development:
Daniel Abrams, Acting CEO, CSO/CMO, Sierra Neuropharmaceuticals
Thomas King, President and CEO, Alexza Pharmaceuticals
Paul McGonigle, Vice President External Scientific Affairs, PsychoGenics
Will Rosellini, President and CEO, MicroTransponder
Session Chair: Jeff Calcagno, Principal, Scale Venture Partners

Neurodegenerative Disease: Alzheimer's and Parkinson's:
Steve Orndorff, President and CEO, Accera
John Mordock, President and CEO, Neurologix
Daryl Kipke, President and CEO, NeuroNexus Technologies
Richard Hadden, President and CEO, Cytox
Session Chair: John Reher, Managing Director, Brain Trust Accelerator Fund

Neuroscience Research & Development Partnerships:
Mary Chamberlain, Global External R&D, Lilly Research Labs, Eli Lilly
Carol Greve-Philips, Vice President, Corporate Development, Genzyme
Dave Schulz, Senior Director, Worldwide Business Development, Pfizer
Todd Whitehurst, Vice President Emerging Indications, Boston Scientific
Moderator: Dan O'Connell, Managing Partner, NeuroVentures Capital

Neuroregeneration and Stem Cells:
Deborah Eppstein, President and CEO, Q Therapeutics
Andres Haegerstrand, Chief Scientific Officer, NeuroNova
Jonathan Kil, President and CEO, Sound Pharmaceuticals
Martin McGlynn, President and CEO, StemCells, Inc.
Session Chair: Frank Eeckman, NeuroInsights, NIO

NeuroVaccines, The Use of Vaccines in Neurology and Psychiatry:
Raafat Fahim, President and CEO, Nabi
Mark Schwartz, President and CEO, Bayhill Therapeutics
Walter Schmidt, CEO, Affiris
Session Chair: Roger Quy, General Partner, Technology Partners

Traumatic Injury: Stroke, Traumatic Brain Injury, and Spinal Cord Injury:
Martin Dieck, President and CEO, Nfocus Neuromedical
Shawn Lunney, CEO, Neurolutions
Vincent Simmon, President and CEO, Xytis
Michael Singer, CEO, BrainScope
Session Chair: Teo Forcht Dagi, Partner, HLM Venture Partners

Neuroscience Translation, Tech Transfer and Collaboration Opportunities:
Jamie Driscoll, Chief of Research Services, NIMH
Jill Heemskerk, Acting Director, Office of Translational Research, NINDS
Joe Pancrazio, Program Director, Extramural, Repair & Plasticity Cluster,
NINDS Session Chair: Melissa Maderia, Technology Transfer Specialist, NINDS

And that's just for starters.